- Company
- Lotte Biologics advances CDMO Biz with Roche Diagnostics
- by Jung, Sae-Im Aug 10, 2023 05:33am
- On the 9th, Lotte Biologics announced that it had recently signed a Memorandum of Understanding (MOU) with Roche Diagnostics, the diagnostic division of the Roche Group, to advance the productivity and quality of its Contract Development and Manufacturing Organization (CDMO) business. The MOU, which was signed at Penzberg, where Roche Dia
- Company
- Generic drugs occupy over 70% of tamsulosin market
- by Kim, Jin-Gu Aug 10, 2023 05:33am
- The share of generic drugs in the market for prostatic hyperplasia treatments that contain tamsulosin exceeded 70%. This is interpreted as an effect of the rapid rise in generic sales while the prescription performance of original products slowed down. One variable in this market is impurities. At the end of June, impurities were detected i
- Company
- Patent dispute over Entresto's patents continue
- by Kim, Jin-Gu Aug 10, 2023 05:33am
- The patent dispute over ‘Entresto (sacubitril/valsartan),’ a chronic heart failure treatment with an annual prescription of more than KRW 40 billion, has been ongoing for over 2 years now. Novartis, the company that owns the original drug, is actively pursuing a defense strategy against generic companies' patent challenges. Novartis app
- Company
- Chong Kun Dang/Cell Biotech, big match in the MicrobiomeCDMO
- by Nho, Byung Chul Aug 8, 2023 05:30am
- It is expected that CKD Bio and Cell Biotech will compete to expand the related market in the microbiome drug CDMO (Contract Development Manufacturing) field. According to the Korea Institute of Science and Technology Information, the global market for human microbiome is expected to reach 1,743.8 billion won in 2029 with a rapid average annu
- Company
- Union Korea Pharm agrees to export 8 drugs to Jurabek
- by Lee, Seok-Jun Aug 8, 2023 05:30am
- Union Korea Pharm signed an agreement to export 8 types of drugs with its Uzbekistan partner, Jurabek Laboratories. According to the company on the 7th, the 8 export items include the company’s representative antibiotics and injections such as Atrasen Tab, Serokfen Tab, Uni-Minoxidil Tab, Atorvan Tab, Kefodon Inj, and Amikacin Inj. Th
- Company
- Immuno-anticancer drugs have brought us closer
- by Jung, Sae-Im Aug 8, 2023 05:30am
- Immuno-anticancer agents are active in early lung cancer. Following 'Opdivo (Nivolumab),' which obtained the indication for adjuvant therapy before surgery for the first time, 'Keytruda (Pembrolizumab)' is also seeking to expand its scope as adjuvant therapy before and after surgery. The data shown by immuno-anticancer drugs in early lung
- Company
- ‘Competitors eye Eylea due to its many benefits’
- by Jung, Sae-Im Aug 8, 2023 05:30am
- The fact that many companies are concentrating on the development of Eylea biosimilars is proof of the many advantages owned by Eylea. We plan to continue to make known the strengths of Eylea while developing new products to continue to deliver on our patient and HCP-centric treatment strategy.” Sangok Suh, Head of the Specialty Medicine bus
- Company
- Sales of the flu tx market increased due to the endemic
- by Chon, Seung-Hyun Aug 7, 2023 05:23am
- In the first half of the year, the outpatient prescription market for flu treatment exceeded 10 billion won in four years. As the number of flu patients surged after the end of the Corona 19 pandemic, the flu treatment market, which had disappeared over the past three years, expanded significantly. According to UBIST, a drug research institut
- Company
- Prescription of HA eye drops record KRW 166 bil in 1H
- by Kim, Jin-Gu Aug 7, 2023 05:23am
- The prescription market for hyaluronic acid eye drops grew to record the largest scale ever ahead of the reimbursement reevaluations set for the end of this year. In 1H alone, the market grew exceeded KRW 160 billion in prescriptions this year. The number of companies with half-year prescriptions that exceed KRW 10 billion increased fro
- Company
- Prescriptions of pseudoephedrine rise 35% in 1H
- by Chon, Seung-Hyun Aug 4, 2023 05:38am
- The prescription market for ‘pseudoephedrine,’ which continues to show an unstable supply and demand in the market, has expanded significantly. Despite the end of the pandemic, demand for the drug has increased significantly due to the increase in flu and cold patients. Accordingly, the need to raise the insurance price ceiling for the low-pri
